ClinicalTrials.gg
CompletedNCT00977860Updated May 2, 2024Results posted

Hypofractionated SBRT For Prostate Cancer

An interventional study of Stereotactic Body Radiation Therapy in Prostate Cancer, sponsored by Adam Olson. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Adam Olson · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
624th of 3,024
163 · median 48
Started
2010
with 104 others
No phase
764 of 3,597
157 open now
Registered
1,025th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 624th largest by enrollment of the 3,024 interventional ones that give a count, is one of 105 that started in 2010, is one of 764 with no phase, and was the 1,025th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at 2 years following hypofractionated stereotactic body radiation therapy for low and intermediate risk prostate cancer.

Read the detailed description

Radiosurgery should be ideal for treating prostate cancer because:

  • targeting accuracy for static targets is excellent, with an error of about 1mm,
  • it can adjust for intra-fractional organ motion, reducing the volume of the target PTV and therefore the dose to surrounding organs,
  • by using over one-hundred non-conplanar beams, the dose gradient between the prostate and surrounding tissues may be superior to that achieved with conventional linear accelerators,
  • the radiobiology of prostate cancer may favor large dose per fractions.
03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate
  • Stereotactic
  • Radiosurgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven prostate adenocarcinoma
  • Gleason score 2-7
  • within one year of date of registration
  • Clinical stage T1b-T2b, N0-Nx, M0-Mx (AJCC 6th Edition)
  • T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, CT, and/or MRI)
  • M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous .
  • PSA ≤ 20 ng/dL
  • Patients belonging in one of the following risk groups:
  • Low: CS T1b-T2a and Gleason 2-6 and PSA ≤ 10, or
  • Intermediate: CS T2b and Gleason 2-6 and PSA ≤ 10, or CS T1b-T2b, and Gleason 2-6 and PSA ≤ 20 ng/dL, or Gleason 7 and PSA ≤ 10 ng/dL
  • Prostate volume: ≤ 100 cc
  • Determined using: volume = π/6 x length x height x width
  • Measurement from CT or ultrasound ≤90 days prior to registration.
  • performance status 0-1
  • Completion of patient questionnaires:FACT-G questionnaire, AUA questionnaire, EPIC-26 questionnaire, SHIM questionnaire, Utilization of Sexual Medications/Devices questionnaire
  • Consent signed.

Exclusion criteria

Exclusion Criteria:

  • Prior prostatectomy or cryotherapy of the prostate
  • Prior radiotherapy to the prostate or lower pelvis
  • Implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.
  • Chemotherapy for a in the last 5 years.
  • History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years.
  • Hormone ablation for two months prior to enrollment, or during treat
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Other
    SBRT

    Radiation: Stereotactic Body Radiation Therapy

Interventions

  • RadiationStereotactic Body Radiation Therapy

    36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period

    Also known as: CyberKnife, Trilogy, True Beam, Radiosurgery

06

What researchers measure

Primary outcomes

  1. Rate of Acute Grade 3 or Higher GI and GU Toxicities

    Number of patients experiencing acute grade 3 or higher GI and GU toxicities. Acute toxicities are those occurring within 90 days of start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

    Time frame: Up to 90 days

  2. Rate of Late Grade 3 or Higher GI and GU Toxicities

    Number of patients experiencing late grade 3 or higher GI and GU toxicities. Late toxicities are those occurring after 90 days post start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

    Time frame: After 90 days post-treatment, up to 5 years per patient

  3. Biochemical Disease-Free Survival Rate (bDFS)

    Biochemical Disease-Free Survival (bDFS) as defined by Phoenix and ASTRO. Biochemical progression-free survival events were defined as PSA of ≥ 0.4 ng/mL following postoperative radiotherapy, PSA \> 2.0 ng/mL at any time, clinical progression, initiation of non-protocol hormone therapy, and death from any cause.

    Time frame: Up to 5 years

Secondary outcomes

  1. Rate of Local Failure

    Proportion of patients with 'local failure', which is defined as clinical evidence local recurrence. Clinical failure includes a palpable abnormality that has increased in size, failure of regression of a palpable abnormality, or redevelopment of a prostate abnormality after complete response, further confirmed by prostate biopsy.

    Time frame: Up to 5 years

  2. Rate of Distant Failure

    Proportion of patients with 'distant failure' (includes regional failure) which is defined as documented clinically via bone scan, CT or other imaging study that shows metastatic disease (disease located distant from the prostate area).

    Time frame: Up to 5 years

  3. 5-year Overall Survival (OS)

    Percentage of patients that remained alive 5 years after start of study treatment. Deaths were from any cause.

    Time frame: At 5 years

  4. Quality of Life (QoL) - FACT-G - Prior to Therapy

    The Functional Assessment of Cancer Therapy- General (FACT-G) is a self-administered 27-item questionnaire designed to measure four domains of HRQOL in cancer patients. It is comprised of physical (PWB), social (SWB), emotional (EWB), and functional (FWB) well-being subscales: (PWB; 7-items, score range 0-28), (SWB; 7-items, score range 0-28), (EWB; 6-items, score range 0-24), (FWB; 7-items, score range 0-28). The FACT-G generates an overall score of 0-108). All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much) and asks information regarding the patients last 7 days.

    Time frame: Prior to start of therapy

  5. Quality of Life (QoL) - FACT-G - At 24 Months

    The Functional Assessment of Cancer Therapy- General (FACT-G) is a self-administered 27-item questionnaire designed to measure four domains of HRQOL in cancer patients. It is comprised of physical (PWB), social (SWB), emotional (EWB), and functional (FWB) well-being subscales: (PWB; 7-items, score range 0-28), (SWB; 7-items, score range 0-28), (EWB; 6-items, score range 0-24), (FWB; 7-items, score range 0-28). The FACT-G generates an overall score of 0-108). All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much) and asks information regarding the patients last 7 days.

    Time frame: At 24 months (post-start of therapy)

07

Results

Posted May 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneSBRT
Started163
Completed163
Not completed0

Outcome measures

PrimaryRate of Acute Grade 3 or Higher GI and GU Toxicities

Number of patients experiencing acute grade 3 or higher GI and GU toxicities. Acute toxicities are those occurring within 90 days of start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Rate of Acute Grade 3 or Higher GI and GU Toxicities
ParticipantsSBRT
Rate of Acute Grade 3 or Higher GI and GU Toxicities2
PrimaryRate of Late Grade 3 or Higher GI and GU Toxicities

Number of patients experiencing late grade 3 or higher GI and GU toxicities. Late toxicities are those occurring after 90 days post start of treatment, assessed using the NCI Common Toxicity Criteria (CTCAE) version 3.0.

Time frame:
After 90 days post-treatment, up to 5 years per patient
Reported as:
Count of participants · Participants
Rate of Late Grade 3 or Higher GI and GU Toxicities
ParticipantsSBRT
Rate of Late Grade 3 or Higher GI and GU Toxicities0
PrimaryBiochemical Disease-Free Survival Rate (bDFS)

Biochemical Disease-Free Survival (bDFS) as defined by Phoenix and ASTRO. Biochemical progression-free survival events were defined as PSA of ≥ 0.4 ng/mL following postoperative radiotherapy, PSA \> 2.0 ng/mL at any time, clinical progression, initiation of non-protocol hormone therapy, and death from any cause.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Biochemical Disease-Free Survival Rate (bDFS)
ParticipantsSBRT
Biochemical Disease-Free Survival Rate (bDFS)7
SecondaryRate of Local Failure

Proportion of patients with 'local failure', which is defined as clinical evidence local recurrence. Clinical failure includes a palpable abnormality that has increased in size, failure of regression of a palpable abnormality, or redevelopment of a prostate abnormality after complete response, further confirmed by prostate biopsy.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryRate of Distant Failure

Proportion of patients with 'distant failure' (includes regional failure) which is defined as documented clinically via bone scan, CT or other imaging study that shows metastatic disease (disease located distant from the prostate area).

Time frame:
Up to 5 years

No measurements were reported for this outcome.

Secondary5-year Overall Survival (OS)

Percentage of patients that remained alive 5 years after start of study treatment. Deaths were from any cause.

Time frame:
At 5 years
Reported as:
Number · percentage of participants
5-year Overall Survival (OS)
percentage of participantsSBRT
5-year Overall Survival (OS)93.87
SecondaryQuality of Life (QoL) - FACT-G - Prior to Therapy

The Functional Assessment of Cancer Therapy- General (FACT-G) is a self-administered 27-item questionnaire designed to measure four domains of HRQOL in cancer patients. It is comprised of physical (PWB), social (SWB), emotional (EWB), and functional (FWB) well-being subscales: (PWB; 7-items, score range 0-28), (SWB; 7-items, score range 0-28), (EWB; 6-items, score range 0-24), (FWB; 7-items, score range 0-28). The FACT-G generates an overall score of 0-108). All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much) and asks information regarding the patients last 7 days.

Time frame:
Prior to start of therapy
Reported as:
Mean · score on a scale
Quality of Life (QoL) - FACT-G - Prior to Therapy
score on a scaleSBRT
PWB26.06019 ± 2.716213
SWB23.70186 ± 3.641432
EWB19.58 ± 4.449
FWB23.44 ± 5.417
FACTG92.78983 ± 12.323307
SecondaryQuality of Life (QoL) - FACT-G - At 24 Months

The Functional Assessment of Cancer Therapy- General (FACT-G) is a self-administered 27-item questionnaire designed to measure four domains of HRQOL in cancer patients. It is comprised of physical (PWB), social (SWB), emotional (EWB), and functional (FWB) well-being subscales: (PWB; 7-items, score range 0-28), (SWB; 7-items, score range 0-28), (EWB; 6-items, score range 0-24), (FWB; 7-items, score range 0-28). The FACT-G generates an overall score of 0-108). All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much) and asks information regarding the patients last 7 days.

Time frame:
At 24 months (post-start of therapy)
Reported as:
Mean · score on a scale
Quality of Life (QoL) - FACT-G - At 24 Months
score on a scaleSBRT
PWB26.10 ± 2.791
SWB21.95238 ± 6.645819
EWB21.25 ± 3.370
FWB22.85 ± 5.824
FACTG93.15000 ± 14.605211

Adverse events

Collected over Adverse event data were collected for a period of up to 5 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SBRT15/163 (9.2%)2/163 (1.2%)9/163 (5.5%)
Most frequent serious events
Most frequent serious events
EventSBRT
IncontinenceRenal and urinary disorders1/163
NocturiaRenal and urinary disorders1/163
HematuriaRenal and urinary disorders1/163
Urinary frequncyRenal and urinary disorders1/163
DysuriaRenal and urinary disorders1/163
Most frequent other events
Most frequent other events
EventSBRT
Urinary frequency/urgencyRenal and urinary disorders8/163
DiarrheaGastrointestinal disorders5/163
OtherRenal and urinary disorders3/163
Fatigue (asthenia, lethargy, malaise)General disorders2/163
nocturiaRenal and urinary disorders1/163
weak streamRenal and urinary disorders1/163
hypercholesteremiaInvestigations1/163
Burning - tip of penisSkin and subcutaneous tissue disorders1/163
anxietyPsychiatric disorders1/163

Baseline characteristics

Age, Continuous
Age, Continuous(years)SBRT
Mean67.80 ± 6.929
Sex: Female, Male
Sex: Female, Male(Participants)SBRT
Female0
Male163
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SBRT
Hispanic or Latino0
Not Hispanic or Latino162
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SBRT
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American12
White148
More than one race0
Unknown or Not Reported1
08

Study locations

1 site
  • UPMC Hillman Cancer Center - Shadyside Radiation Oncology
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Jul 2022, 141 months.

Results were first posted in May 2024, 1 year 9 months after primary completion. A results delay was requested in Jul 2023.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 141 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2009
First posted
Sep 16, 2009
StartActual
Oct 7, 2010
Primary completionActual
Jul 8, 2022
CompletionActual
Jul 8, 2022
Results delay requested
Jul 3, 2023
Results first posted
May 2, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00977860
Lead sponsor
Adam Olson
Responsible party
Adam Olson (Clinical Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Sep 16, 2009
Start date
Oct 7, 2010
Primary completion
Jul 8, 2022
Completion
Jul 8, 2022
Results posted
May 2, 2024
Last update
May 2, 2024

Study contacts

Adam Olson, MD
principal investigator · University of Pittsburgh Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion